Riskpilot← Back to searchSign inGet full accessY-mAbs Therapeutics A/S
A/SActiveCVR 37053678Agern Alle 13Research and experimental development on natural sciences and engineering · NACE 7210Est. 201522 employees
Revenue 2024
DKK 74,3M
+5% vs 2023
EBITDA margin
-1.6%
+94% vs 2023
Equity ratio
-472.9%
Financial strength
Net profit 2024
DKK -12,5M
+55% vs 2023
| Revenue | DKK 74,3M | +5% |
| EBITDA | DKK -1,2M | +94% |
| Net profit | DKK -12,5M | +55% |
| Total assets | DKK 26,5M | -53% |
| Equity | DKK -125,2M | -11% |
| Employees | 22 | — |
Legal name
Y-mAbs Therapeutics A/S
CVR number
37053678
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27. august 2015
Share capital
DKK 9.833.332
Employees
22 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør, af to medlemmer af bestyrelsen i forening, af et medlem af bestyrelsen i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Virksomhedens formål er at udvikle lægemidler samen anden hermed forbunden virksomhed.
Address
Agern Alle 13
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 82.434 | 67.550 | 82.332 | 70.656 | 74.263 |
| Staff expenses | -75.828 | -105.682 | -128.511 | -90.965 | -75.459 |
| EBITDA | 6.605 | -38.133 | -46.338 | -20.082 | -1.196 |
| Depreciation & amort. | -1.583 | -2.082 | -30.492 | -806 | -191 |
| EBIT | 5.023 | -40.215 | -76.830 | -20.888 | -1.388 |
| Net financials | -6.225 | -1.873 | -8.856 | -6.860 | -11.113 |
| Profit before tax | -1.202 | -42.088 | -85.686 | -27.749 | -12.500 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -1.202 | -42.088 | -85.686 | -27.749 | -12.500 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 52.038 | 61.472 | 22.906 | 56.658 | 26.470 |
| Equity | 2.833 | -39.255 | -84.941 | -112.690 | -125.190 |
| Long-term debt | 6.331 | 8.379 | 11.600 | 8.264 | 5.829 |
| Short-term debt | 42.874 | 92.348 | 96.246 | 161.084 | 145.832 |
| Total debt | 49.205 | 100.727 | 107.847 | 169.348 | 151.661 |
EBITDA margin
-1.6%
This company
15.8%
Market median
-110% vs market
20202024
Equity ratio
-472.9%
This company
38.2%
Market median
-1338% vs market
20202024
Return on equity
-1250046400.0%
This company
18.4%
Market median
-6793730535% vs market
20202024
Net profit margin
-16.8%
This company
8.1%
Market median
-307% vs market
20202024
Asset turnover
2.81×
This company
1.12×
Market median
+151% vs market
20202024
Debt / equity
1.21×
This company
0.62×
Market median
-95% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
YT Founder | Founder | 2015 |
VS Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (2) | ||
CJ Management | Management | 2015 – 2022 |
MJ Chief Executive Officer | Chief Executive Officer | 2023 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Former (11) | ||
| Board of Directors | 2018 – 2021 | |
| Chairman | 2024 – 2025 | |
BK | Chairman | 2022 – 2024 |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2016 – 2020 | |
| Board of Directors | 2025 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2018 – 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Y-mAbs Therapeutics A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Y-MABS THERAPEUTICS, INC. | Founder | 0 companies |
| Claus Juan Møller-San Pedro | Management | 0 companies |
| Michael Joseph Rossi | Chief Executive Officer | 0 companies |
| Vincent Sainte-Catherine | Chief Executive Officer | 0 companies |
| David Neil Gill | Board of Directors | 0 companies |
| Thomas Gad | Chairman | 0 companies |
| Bo Kruse | Chairman | 0 companies |
| Gérard Ber | Board of Directors | 0 companies |
| Jim Irvin Healy | Board of Directors | 0 companies |
| Laura J. Hamill | Board of Directors | 0 companies |
| Julien Forest | Board of Directors | 0 companies |
| Ashutosh Tyagi | Board of Directors | 0 companies |
| Gregory Stephen Raskin | Board of Directors | 0 companies |
| Peter Paul Pfreundschuh | Board of Directors | 0 companies |
| Johan Ernst Wedell-Wedellsborg | Board of Directors | 0 companies |
| Antoine Bernasconi | Chairman | 0 companies |
| Michael Joachim Buschle | Board of Directors | 0 companies |